Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET

Company Participants

Hayleigh Collins - Director and Head of Corporate Communications

Sean Nolan - CEO

Sukumar Nagendran - President and Head of Research and Development

Salman Bhai - Assistant Professor of Neurology at UT

Kamran Alam - CFO

Conference Call Participants

Abigail Gray - Baird

Gil Blum - Needham & Co.

Operator

Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene Therapies First Quarter 2023 Earnings Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there'll be an opportunity to ask questions. [Operator Instructions]

I would now like to turn the conference over to Hayleigh Collins, Director, Head of Corporate Communications. Please go ahead.

Hayleigh Collins

Thank you. Good afternoon and welcome to Taysha's first quarter 2023 financial results and corporate update conference call. Earlier today Taysha issued a press release announcing financial results for the first quarter 2023. A copy of this press release is available on the Company's website and through our SEC filings.

Joining me on today's call are Sean Nolan, Taysha's CEO, Sukumar Nagendran, President and Head of Research & Development; Kamran Alam, Chief Financial Officer and Salman Bhai, Assistant Professor of Neurology at UT, Southwestern. We will hold a question-and-answer session following our prepared remarks.

Please note that on today's call, we will be making forward-looking statements, including statements relating to the existing clinical data for TSHA-120 the therapeutic and commercial potential of TSHA-120 and TSHA-102. These statements may include expected timing and results of clinical trials of our product candidates and other clinical and regulatory plans and the market opportunity for those programs.

This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway and future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not of historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements.

These risks include uncertainties related to the timing and results of clinical trials of, and regulatory interactions for our product candidates, our dependence upon strategic alliances and other third-party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties and the requirements of substantial funding to conduct our research and development activities.